- ICH GCP
- Реестр клинических исследований США
- Клиническое испытание NCT02503137
Исследование SM04554, нанесенного местно на кожу головы мужчин с андрогенетической алопецией, проанализированной с помощью биопсии кожи головы до и после введения дозы
Фаза 2, многоцентровое, рандомизированное, двойное слепое исследование SM04554, применяемого местно на кожу головы мужчин с андрогенетической алопецией (АГА), проанализированное с помощью биопсии кожи головы до и после введения дозы.
This study will assess the safety, tolerability, and efficacy of SM04554 at concentrations of 0.15% and 0.25%. Improved knowledge of the changes in hair counts and immunohistochemical analysis associated with androgenetic alopecia (AGA) before and after treatment with SM04554 and compared to placebo may lead to a greater understanding of the underlying mechanisms of action of SM04554.
Обзор исследования
Статус
Условия
Вмешательство/лечение
Тип исследования
Регистрация (Действительный)
Фаза
- Фаза 2
Контакты и местонахождение
Места учебы
-
-
Michigan
-
Clinton Township, Michigan, Соединенные Штаты
- Research Site
-
-
Ohio
-
Cleveland, Ohio, Соединенные Штаты
- Research Site
-
-
Texas
-
College Station, Texas, Соединенные Штаты
- Research Site
-
Houston, Texas, Соединенные Штаты
- Research Site
-
-
Virginia
-
Lynchburg, Virginia, Соединенные Штаты
- Research Site
-
-
Критерии участия
Критерии приемлемости
Возраст, подходящий для обучения
Принимает здоровых добровольцев
Полы, имеющие право на обучение
Описание
Inclusion Criteria:
- Clinical diagnosis of AGA with Norwood-Hamilton Classification score of 4, 5, 5A, 5V, or 6
- In good general health, as determined by the Investigator
- Willing and able to attend all study visits
- Willing to undergo two punch biopsies of the scalp
- Willing to inform females, with whom they may interact, that they are using a topical investigational product and direct contact should be avoided as potential harm to a fetus is unknown
- Willing to not use permanent or semi-permanent hair products (e.g., color, texturizers, relaxers) for the duration of the study; daily styling products will be allowed on non-study visit days (e.g., hair gel, mousse, styling spray)
- Willing to use sponsor-supplied shampoo and conditioner in place of regular shampoo and conditioner, for the duration of the study; use of sponsor-supplied conditioner is optional for subjects who do not use conditioner
Exclusion Criteria:
- Clinical diagnosis of alopecia areata or other non-AGA forms of alopecia
- Scalp hair loss on the treatment area, due to disease, injury, or medical therapy
- Males who are sexually active and have a partner who is capable of becoming pregnant, neither of whom have had surgery to become sterilized, that are not using a highly effective method of birth control and are not willing to use a highly effective method of birth control during the study treatment period until 90 days post last dose of study medication
- Current skin disease (e.g., psoriasis, atopic dermatitis, eczema, sun damage, seborrheic dermatitis, actinic keratosis), cuts and/or abrasions on the scalp or hands or condition (e.g., sunburn, tattoos) on the treatment area or hands that, in the opinion of the Investigator, might put the subject at risk or interfere with the study conduct or evaluations
- History of or current skin cancer (e.g., melanoma, basal cell carcinoma, squamous cell carcinoma) located anywhere on the body
- History of surgical correction of hair loss on the scalp
- Previous exposure to SM04554
- Use of blood thinners (e.g., Coumadin, Plavix, Lovenox, and aspirin >81mg); low dose aspirin (e.g., ≤81 mg) is allowable
- Use of any products or devices clinically proven to promote scalp hair growth (e.g., finasteride or minoxidil) within 24 weeks prior to study start
- Use of anti-androgenic therapies (e.g., spironolactone, flutamide, cyproterone acetate, cimetidine) within 12 weeks prior to study start
- Use of semi-permanent hair products (e.g., color, texturizers, relaxers) within 30 days prior to study start
- Use of medicated shampoo or conditioner (medicated shampoo and conditioner refer to any prescription shampoo or conditioner as well as any over-the-counter medicated shampoo or conditioner, such as those for treatment of dandruff or promoting hair growth) within 30 days prior to study start
- History of hair transplants
- Current use of an occlusive wig, hair extensions, or hair weaves
- Participation in any other investigational drug or medical device trial which included administration of an investigational study medication or medical device, within 30 days or 5 half-lives of the investigational agent, whichever is longer, prior to study start
- Poor peripheral venous access
- Subjects unwilling to refrain from sperm donation during the study treatment period until 90 days post last dose of study medication
- Subjects with pregnant partners at study start
- Subjects who are immediate family members (spouse, parent, child, or sibling; biological or legally adopted) of personnel directly affiliated with the study at the investigative site, or are directly affiliated with the study at the investigative site
- Subjects employed by Samumed, LLC, or any of its affiliates or development partners (that is, an employee, temporary contract worker, or designee) responsible for the conduct of the study
Учебный план
Как устроено исследование?
Детали дизайна
- Основная цель: Уход
- Распределение: Рандомизированный
- Интервенционная модель: Параллельное назначение
- Маскировка: Тройной
Оружие и интервенции
Группа участников / Армия |
Вмешательство/лечение |
|---|---|
|
Экспериментальный: Topical SM04554 0.15% solution
Topical SM04554 0.15% solution, once daily for approximately 90 days |
Study medication application will be performed by the individual subject at approximately the same time each day. |
|
Экспериментальный: Topical SM04554 0.25% solution
Topical SM04554 0.25% solution, once daily for approximately 90 days |
Study medication application will be performed by the individual subject at approximately the same time each day. |
|
Плацебо Компаратор: Vehicle
Topical vehicle solution, once daily for approximately 90 days |
Vehicle solution application will be performed by the individual subject at approximately the same time each day. |
Что измеряет исследование?
Первичные показатели результатов
Мера результата |
Мера Описание |
Временное ограничение |
|---|---|---|
|
Change From Baseline/Day 91 in Number of Terminal Hair Follicles (Terminal Anagen + Terminal Catagen and Telogen Follicles)
Временное ограничение: Day 91 and Day 135
|
Scalp biopsies were used to analyze the outcome measure at baseline (prior to initiating therapy) and at each subsequent timepoint. Change from baseline is the difference between follow-up and baseline. Change from Day 91 is the difference between Day 135 and Day 91. |
Day 91 and Day 135
|
|
Change From Baseline/Day 91 in Number of Terminal Anagen Hair Follicles
Временное ограничение: Day 91 and Day 135
|
Scalp biopsies were used to analyze the outcome measure at baseline (prior to initiating therapy) and at each subsequent timepoint. Change from baseline is the difference between follow-up and baseline. Change from Day 91 is the difference between Day 135 and Day 91. |
Day 91 and Day 135
|
|
Change From Baseline/Day 91 in Number of Terminal Catagen and Telogen Hair Follicles
Временное ограничение: Day 91 and Day 135
|
Scalp biopsies were used to analyze the outcome measure at baseline (prior to initiating therapy) and at each subsequent timepoint. Change from baseline is the difference between follow-up and baseline. Change from Day 91 is the difference between Day 135 and Day 91. |
Day 91 and Day 135
|
|
Change From Baseline/Day 91 in Number of Miniaturized Hair Follicles (Indeterminate + Vellus Follicles)
Временное ограничение: Day 91 and Day 135
|
Scalp biopsies were used to analyze the outcome measure at baseline (prior to initiating therapy) and at each subsequent timepoint. Change from baseline is the difference between follow-up and baseline. Change from Day 91 is the difference between Day 135 and Day 91. |
Day 91 and Day 135
|
|
Change From Baseline/Day 91 in Number of Indeterminate Hair Follicles
Временное ограничение: Day 91 and Day 135
|
Scalp biopsies were used to analyze the outcome measure at baseline (prior to initiating therapy) and at each subsequent timepoint. Change from baseline is the difference between follow-up and baseline. Change from Day 91 is the difference between Day 135 and Day 91. |
Day 91 and Day 135
|
|
Change From Baseline/Day 91 in Number of Vellus Hair Follicles
Временное ограничение: Day 91 and Day 135
|
Scalp biopsies were used to analyze the outcome measure at baseline (prior to initiating therapy) and at each subsequent timepoint. Change from baseline is the difference between follow-up and baseline. Change from Day 91 is the difference between Day 135 and Day 91. |
Day 91 and Day 135
|
Вторичные показатели результатов
Мера результата |
Мера Описание |
Временное ограничение |
|---|---|---|
|
Terminal and Miniaturized Hair Follicle Density/mm²
Временное ограничение: Day 91 and Day 135
|
Scalp biopsies were used to analyze the outcome measure at baseline (prior to initiating therapy) and at each subsequent timepoint. Change from baseline is the difference between follow-up and baseline. Change from Day 91 is the difference between Day 135 and Day 91. |
Day 91 and Day 135
|
|
Ratio of Terminal to Miniaturized Hair Follicles
Временное ограничение: Day 91 and Day 135
|
Scalp biopsies were used to analyze the outcome measure at baseline (prior to initiating therapy) and at each subsequent timepoint. Change from baseline is the difference between follow-up and baseline. Change from Day 91 is the difference between Day 135 and Day 91. |
Day 91 and Day 135
|
|
Beta-catenin in Epidermis and Infundibulum
Временное ограничение: Day 91 and Day 135
|
Immunohistochemistry of scalp biopsies were used to analyze the nuclear expression outcome measure at baseline (prior to initiating therapy) and at each subsequent timepoint. Percentage of positively-stained nuclei were reported at each timepoint. Change from baseline in percentage of positively-stained nuclei is the difference between follow-up and baseline. Change from Day 91 is the difference between Day 135 and Day 91. |
Day 91 and Day 135
|
|
Ki-67 in Epidermis and Infundibulum
Временное ограничение: Day 91 and Day 135
|
Immunohistochemistry of scalp biopsies were used to analyze the nuclear expression outcome measure at baseline (prior to initiating therapy) and at each subsequent timepoint. Percentage of positively-stained nuclei were reported at each timepoint. Change from baseline in percentage of positively-stained nuclei is the difference between follow-up and baseline. Change from Day 91 is the difference between Day 135 and Day 91. |
Day 91 and Day 135
|
|
Ki-67 in Hair Bulb
Временное ограничение: Day 91 and Day 135
|
Immunohistochemistry of scalp biopsies were used to analyze the nuclear expression outcome measure at baseline (prior to initiating therapy) and at each subsequent timepoint. Percentage of positively-stained nuclei were reported at each timepoint. Change from baseline in percentage of positively-stained nuclei is the difference between follow-up and baseline. Change from Day 91 is the difference between Day 135 and Day 91. |
Day 91 and Day 135
|
Соавторы и исследователи
Спонсор
Следователи
- Директор по исследованиям: Yusuf Yazici, M.D., Biosplice Therapeutics, Inc.
Даты записи исследования
Изучение основных дат
Начало исследования
Первичное завершение (Действительный)
Завершение исследования (Действительный)
Даты регистрации исследования
Первый отправленный
Впервые представлено, что соответствует критериям контроля качества
Первый опубликованный (Оцененный)
Обновления учебных записей
Последнее опубликованное обновление (Действительный)
Последнее отправленное обновление, отвечающее критериям контроля качества
Последняя проверка
Дополнительная информация
Термины, связанные с этим исследованием
Ключевые слова
Дополнительные соответствующие термины MeSH
Другие идентификационные номера исследования
- SM04554-AGA-04
Информация о лекарствах и устройствах, исследовательские документы
Изучает лекарственный продукт, регулируемый FDA США.
Изучает продукт устройства, регулируемый Управлением по санитарному надзору за качеством пищевых продуктов и медикаментов США.
Эта информация была получена непосредственно с веб-сайта clinicaltrials.gov без каких-либо изменений. Если у вас есть запросы на изменение, удаление или обновление сведений об исследовании, обращайтесь по адресу register@clinicaltrials.gov. Как только изменение будет реализовано на clinicaltrials.gov, оно будет автоматически обновлено и на нашем веб-сайте. .